Takeda’s oral narcolepsy drug shines in two Phase III trials
Of the patients across the two Phase III studies, more than 95% enrolled in the ongoing long-term extension (LTE) study.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
